CNTG - Twist Bioscience Centogene launch sequencing panels for rare disease cancer research
- Twist Bioscience ( NASDAQ: TWST ) and Centogene ( NASDAQ: CNTG ) said they launched three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and diagnostics.
- Target enrichment panels enable in-depth sequencing on target genes, reducing the need for comprehensive sequencing. This allows for sensitive detection of target genetic sequences and confidence that variants will be detected, the companies added.
- All three new Alliance Panels are curated using the CENTOGENE Biodatabank, with nearly 700K patients represented from over 120 highly countries, over 70% of whom are of non-European descent, according to the companies.
For further details see:
Twist Bioscience, Centogene launch sequencing panels for rare disease, cancer research